4Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
5Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
6Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
7Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
8Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
9Casellas J M,Gilardoni M,Tome G,et al,Comparative in vitro activity of levofloxacin against isolates of bacteria from adult patients with community acquired lower respiratory tract infections[J].J Antimicrob Chemother,1999,43(Suppl C):37-42.
10Preston SL,Drusano GL,Bernan AL,et al.Levofloxacin population pharmacokinetics and a creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infecuion[J].Antimicrob Agents Chemother,1998,42(5
